Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer

Area of Science:

• Oncology
• Immunotherapy
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) management has been transformed by targeted therapies and immune checkpoint inhibitors (ICIs).
• The efficacy of ICIs is established in NSCLC lacking specific driver mutations.
• The role of ICIs in driver mutation-positive NSCLC remains less clear.

Purpose of the Study:

• To review the current understanding of immune checkpoint inhibitor (ICI) utilization in driver mutation-positive non-small cell lung cancer (NSCLC).
• To clarify the place of ICIs in the treatment landscape for NSCLC with specific driver mutations.

Main Methods:

• Literature review of current research on immune checkpoint inhibitors and targeted therapies in NSCLC.
• Synthesis of evidence regarding the efficacy and limitations of ICIs in driver mutation-positive NSCLC.

Main Results:

• Immune checkpoint inhibition, particularly in combination with chemotherapy and antiangiogenesis, may offer benefits in recurrent driver mutation-positive NSCLC post-tyrosine kinase inhibitor therapy.
• Current data suggests a limited role for ICIs as a primary treatment in this patient group.

Conclusions:

• The application of immune checkpoint inhibitors in driver mutation-positive NSCLC is currently restricted.
• ICIs can be considered for combination therapy in second- and later-line settings when no other specific treatment options exist.